Skip to content
2000
Volume 21, Issue 6
  • ISSN: 1573-403X
  • E-ISSN: 1875-6557

Abstract

Introduction

The concomitant use of PPIs with antiplatelet therapy remains controversial due to potential drug interactions affecting clinical outcomes. While PPIs are recommended for gastroprotection in patients receiving antiplatelet therapy, concerns persist regarding their impact on antiplatelet efficacy, particularly with dual antiplatelet therapy (DAPT).

Aims

The aim of this study is to evaluate the safety profiles of antiplatelet-proton pump inhibitors (PPIs) combinations and assess the clinical implications of their concurrent use in real-world settings through pharmacovigilance data analysis.

Objectives

The objective of this study is to analyze and compare the thrombo-embolic risk profiles of various antiplatelet-PPI combinations using the FDA Adverse Event Reporting System database.

Methods

We conducted a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database to evaluate the thrombo-embolic risk associated with antiplatelet-PPI combinations. The reporting odds ratio (ROR) and information component were calculated to detect safety signals. The interaction signal score (INTSS) was used to assess the protective or harmful effects of adding acetylsalicylic acid to clopidogrel-PPI combinations.

Results and Discussion

Analysis revealed significant safety signals for thrombo-embolic events with clopidogrel-rabeprazole (ROR: 62.67, 95% CI: 38.38-102.32) and clopidogrel-omeprazole (ROR: 6.87, 95% CI: 4.89-9.66) combinations. DAPT-PPI combinations showed comparable safety profiles to monotherapy-PPI combinations. The INTSS analysis suggested a potential protective effect of acetylsalicylic acid when added to clopidogrel-PPI combinations. Gender-specific analysis revealed female predominance in monotherapy complications and male predominance in combination therapy events. Clinical outcomes, including mortality and hospitalization rates, were comparable between groups.

Conclusion

This pharmacovigilance analysis suggests that while DAPT-PPI combinations demonstrate acceptable safety profiles, careful consideration should be given to PPI selection, particularly given the unexpected safety signals with rabeprazole and confirmed risks with omeprazole. The addition of acetylsalicylic acid to clopidogrel-PPI combinations may offer protective effects against thrombo-embolic events. These findings support individualized risk-benefit assessment in selecting antiplatelet-PPI combinations while ensuring adequate gastroprotection for high-risk patients.

Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X374906250417043907
2025-05-12
2025-10-12
Loading full text...

Full text loading...

References

  1. IqbalA.M. LopezR.A. HaiO. Antiplatelet medications.In: StatPearls.Treasure Island (FL)StatPearls Publishing2025 30725747
    [Google Scholar]
  2. Using clopidogrel with proton pump inhibitors (PPIs). 2023. Available from: https://www.sps.nhs.uk/articles/using-clopidogrel-with-proton-pump-inhibitors-ppis/ (Accessed on: Nov. 20, 2024).
  3. DemcsákA. LantosT. BálintE.R. PPIs are not responsible for elevating cardiovascular risk in patients on clopidogrel - A systematic review and meta-analysis.Front. Physiol.20189155010.3389/fphys.2018.01550 30510515
    [Google Scholar]
  4. LinS.F. LinP.C. ChangC.C. ChangW.L. ChuF.Y. Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay.Medicine (Baltimore)20209950e2369510.1097/MD.0000000000023695 33327360
    [Google Scholar]
  5. LeonardC.E. BilkerW.B. BrensingerC.M. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.Stroke201546372273110.1161/STROKEAHA.114.006866 25657176
    [Google Scholar]
  6. VirkH.U.H. EscobarJ. RodriguezM. Dual antiplatelet therapy: A concise review for clinicians.Life (Basel)2023137158010.3390/life13071580 37511955
    [Google Scholar]
  7. GosaviS. KrishnanG. AcharyaR.V. Aspirin vs clopidogrel: Antiplatelet agent of choice for those with recent bleeding or at risk for gastrointestinal bleed.Cureus2023154e3789010.7759/cureus.37890 37213942
    [Google Scholar]
  8. NiuQ. WangZ. ZhangY. Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease.J. Cardiovasc. Pharmacol. Ther.201722214215210.1177/1074248416663647 27512080
    [Google Scholar]
  9. LuoX. HouM. HeS. Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and meta-analysis.Front. Pharmacol.202313102158410.3389/fphar.2022.1021584 36703730
    [Google Scholar]
  10. CharlotM. GroveE.L. HansenP.R. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: Nationwide propensity score matched study.BMJ2011342d269010.1136/bmj.d2690 21562004
    [Google Scholar]
  11. ChenH.C. TsongY. ChenJ.J. Data mining for signal detection of adverse event safety data.J. Biopharm. Stat.201323114616010.1080/10543406.2013.735780 23331228
    [Google Scholar]
  12. SridharanK. SivaramakrishnanG. Adverse event profile of first-line drugs for treating patent ductus arteriosus in neonates: A disproportionality analysis study of USFDA adverse event reporting system.Paediatr. Drugs202426676778510.1007/s40272‑024‑00657‑3 39367998
    [Google Scholar]
  13. BrownE.G. WoodL. WoodS. The medical dictionary for regulatory activities (MedDRA).Drug Saf.199920210911710.2165/00002018‑199920020‑00002 10082069
    [Google Scholar]
  14. FaillieJ.L. Case–non-case studies: Principle, methods, bias and interpretation.Therapie201974222523210.1016/j.therap.2019.01.006 30773344
    [Google Scholar]
  15. EvansS.J.W. WallerP.C. DavisS. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.Pharmacoepidemiol. Drug Saf.200110648348610.1002/pds.677 11828828
    [Google Scholar]
  16. Prieto-MerinoD. QuarteyG. WangJ. KimJ. Why a Bayesian approach to safety analysis in pharmacovigilance is important.Pharm. Stat.201110655455910.1002/pst.524 22140036
    [Google Scholar]
  17. MuñozM.A. TonningJ.M. BrinkerA.D. DelaneyJ.A.C. GattiJ.C. AviganM. Data mining of the US FDA’s adverse events reporting system database to evaluate drug–drug interactions associated with statin-induced rhabdomyolysis.Pharmaceut. Med.201630632733710.1007/s40290‑016‑0162‑6
    [Google Scholar]
  18. FusaroliM. SalvoF. BegaudB. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): Explanation and elaboration.Drug Saf.202447658559910.1007/s40264‑024‑01423‑7 38713347
    [Google Scholar]
  19. LiangS. MaM. ChenY. The efficacy and safety of proton pump inhibitors combining dual antiplatelet therapy in patients with coronary intervention: A systematic review, meta-analysis and trial sequential analysis of randomized controlled trials.Rev. Cardiovasc. Med.202324823010.31083/j.rcm2408230 39076718
    [Google Scholar]
  20. GuoH. YeZ. HuangR. Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: A systematic review and meta-analysis.Front. Pharmacol.20211269469810.3389/fphar.2021.694698 34408652
    [Google Scholar]
  21. HartmanJ. NaukaP.C. PriyankaS. ChaoJ. WhitsonM.J. Proton pump inhibitors are underprescribed in patients discharged on dual antiplatelet therapy after acute coronary syndrome.Gastroenterology20181551e3710.1053/j.gastro.2018.06.063
    [Google Scholar]
  22. JinaduT. RadhakrishnanA. FanL. Improving use of proton pump inhibitors with dual antiplatelet therapy in patients admitted with acute coronary syndrome.BMJ Open Qual.2022114e00195610.1136/bmjoq‑2022‑001956 36564103
    [Google Scholar]
  23. ValgimigliM. BuenoH. ByrneR.A. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.Eur. Heart J.201839321326010.1093/eurheartj/ehx419 28886622
    [Google Scholar]
  24. Funck-BrentanoC. SzymezakJ. SteichenO. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.Arch. Cardiovasc. Dis.20131061266167110.1016/j.acvd.2013.09.002 24246616
    [Google Scholar]
  25. NagaviJ.B. GurupadayyaB. Platelet aggregation capacity of clopidogrel bisulphate inhibited by rabeprazole and simvastatin in patients undergoing myocardial infarction in a tertiary care system: Drug interaction study.Int J Clin Cardiol20207188
    [Google Scholar]
  26. ChangC.C. ChouY.C. ChangJ.Y. SunC.A. Effects of treatment with clopidogrel with or without proton pump inhibitor omeprazole on the risk of ischemic stroke: A nationwide cohort study.Sci. Rep.2024141168610.1038/s41598‑024‑51682‑8 38242975
    [Google Scholar]
/content/journals/ccr/10.2174/011573403X374906250417043907
Loading
/content/journals/ccr/10.2174/011573403X374906250417043907
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.


  • Article Type:
    Research Article
Keyword(s): antiplatelet therapy; Aspirin; clopidogrel; lansoprazole; omeprazole; rabeprazole
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test